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Background: Guidelines on surgical treatment for kidney cancer (KC) have changed
over the last 10 yr.We present population-based data for patients with KC tumors7 cm
from 2008 to 2013 to investigate whether surgical practice in Norway has changed
according to guidelines.
Objective: To assess the predictors of treatment and survival after KC surgery.
Design, setting, and participants: We identified all surgically treated KC patients with
tumors 7 cm without metastasis diagnosed during 2008–2013 (2420 patients) from
the Cancer Registry of Norway.
Outcome measurements and statistical analysis: Relationships with outcomes were
analyzed using joinpoint regression, multivariate logistic regression, Kaplan-Meier
survival estimates, Cox regression, relative survival (RS), and competing-risk analyses.
Results and limitations: The mean follow-up was 5.2 yr. There was a 28% increase in
the number of patients undergoing surgical treatment over the study period. Joinpoint
regression revealed a significant annual increase in partial nephrectomy (PN) and a small
reduction in radical nephrectomy (RN). PN increased from 43% to 66% for tumors 4 cm
and from 10% to 18% for tumors of 4.1–7 cm. Minimally invasive (MI) RN increased from
53% to 72% andMI PN from25% to 64%, of which 55% of procedureswere performedwith
robotic assistance in 2013. The geographical distribution of treatment approaches
differed significantly. Both PN and MI approaches were more frequent in high-volume
hospitals. Cox regression analysis revealed that PN, age, and Fuhrman grade and stage
were independent predictors of survival. Therewere no significant differences in cancer-
specific survival (p = 0.8). The 5-yr RS for T1a disease was higher after PN than after RN.
Conclusions: The rate of PN for tumors 7 cm increased in the 6-yr study period. MI
approaches increased for both RN and PN. This treatment shift coincides with the new
guideline recommendations in 2010. The possible better survival for patients undergoing
PN compared to RN indicates the importance of following evidence-based guidelines.
Patient summary: The use of partial nephrectomy and minimally invasive surgery for
kidney cancer tumors increased in Norway from 2008 to 2013 according to population-
based data, coinciding with guideline changes. The study illustrate that adherence to
guidelines may improve patient outcomes.
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In Norway, the incidence of kidney cancer (KC) increased by
52% over the course of one decade (2007–2016) [1], with
similar observations in Europe and worldwide [2]. Surgical
treatment is still the mainstay of intervention for localized
KC. Partial nephrectomy (PN) has oncological outcomes
similar to radical nephrectomy (RN) for tumors 7 cm
[3]. Furthermore, several retrospective studies have sug-
gested that PN patients may achieve better overall survival
(OS) [4–7], most likely attributed to lower impairment of
renal function. However, recent publications have chal-
lenged this possible OS gain for PN over RN, claiming that it
is caused by selection bias [8]. Since the early 1990s, the
“pure” laparoscopic and later the robot-assisted laparo-
scopic approach to kidney surgery evolved to complement
the RN and PN open approaches. It has been shown that
minimally invasive methods (MIMs) have equivalent
oncological outcomes to open surgery [9] and add benefits
such as less surgical trauma, lower morbidity, and shorter
hospital stays [10].
From 2006, the European Association of Urology (EAU)
guidelines recommended PN as the standard of care for
tumors 4 cm and as an option in experienced centers for
selected patients with tumors of 4.1–7 cm [11]. In 2010, the
EAU recommendation changed significantly, as PN then
became the standard of care for all tumors 7 cm.
Moreover, a laparoscopic approach was recommended for
RN if PN was not indicated [12].
On this basis, we aimed to establish updated population-
based Norwegian data on KC surgery for tumors 7 cm.
Furthermore, we evaluated adherence to changing guidelines
and the implementation of MIMs and PN. Finally, predictors
for treatment and survival after surgery were assessed.
2. Patients and methods
2.1. Data source, data extraction, exclusions, and quality
assurance
Data sets for all 4465 kidney cancer patients in Norway (ICD-10 code
C64) diagnosed during the 6-yr period from 2008 to 2013were extracted
from the Cancer Registry of Norway (CRN) database. Information on
reporting and the CRN is provided in the Supplementary material. The
data sets consist of demographic, tumor-related, treatment-related, and
follow-up (FU)-related variables. Information on kidney function,
comorbidity, and complication rates was not available. Data quality
assurance and removal of erroneously registered patients (n = 16) was
performed at the CRN, andhas beenpreviouslydescribed [13]. Thereafter,
data sets for 4449 patients were transferred to an anonymous database
for subsequent analyses. Of these, 2420 patients aged>18 yr with N0M0
KC7 cm and surgically treated with PN or RN remainedwithin the data
set. Figure 1 shows details for the inclusion and exclusion of patients. In
accordancewith national regulations, the study did not require informed
consent from the patients when performed at the CRN.
2.2. Definitions used for analyses
Patients were classified as N0M0 if they had no nodal or distant
metastasis at the time of surgery or within 4 mo thereafter. Details onstaging and follow-up are described in the Supplementary material. For
tumor staging, the 2009 version of the TNM classification was used
[14]. Tumor size was based on the histology report, whereas survival and
FU were estimated from data received from the Norwegian Cause of
Death Registry dated December 31, 2016. Open operations were
classified as those that started as open or were converted from a MIM
approach to open surgery. Procedures classified as RN started as RNs or
were PNs converted to RN during surgery. MIMs included pure
laparoscopy, hand-assisted laparoscopy, and robot-assisted laparoscopy.
Norway is subdivided into 19 counties and the health care system is
organized in four regional health authorities (HAs): the Northern (NHA),
Central (CHA), Western (WHA), and South-Eastern (SHA) HAs. Hospitals
performing KC surgery were divided into two groups on the basis of
national volume recommendations according to their mean annual
surgical volume: low-volume hospitals (LVH) performed <20 KC
operations/yr, while high-volume hospitals (HVH) performed 20 KC
operations/yr [13,15]. Hospitals performing fewer than four KC surgeries
during the study were excluded.
2.3. Statistical analysis
Standard descriptive statistics were used, with results presented as the
mean  standard error of the mean (SEM). The median and interquartile
range (IQR) were used for descriptions of variation within groups. We
used t tests and x2 tests for comparisons of continuous and categorical
variables, respectively.
Multiple logistic regression models were established without any
preselection of the variables. Survival estimates, OS and cancer-specific
survival (CSS) were calculated using the Kaplan-Meier method. Relative
survival (RS) was calculated using the Pohar-Perme method [16]. Cox
regression was performed to identify predictors of OS, with the hazard
ratio (HR) and 95% confidence interval (CI) reported. Conditional
probability estimates for death were calculated for different groups
with competing risks. Joinpoint regression analysis was carried out using
Joinpoint Regression v.4.5.0.1 (https://surveillance.cancer.gov/joinpoint)
[17]. Statistical significance was set at p < 0.05. Calculations were




The mean observation time from surgery to death or last FU
was 5.2 yr (median 5.0, range 3.8–6.6). Patients undergoing
RN were older (64.8 vs 61.2 yr; p < 0.001) and had larger
tumors (4.3  0.04 vs 2.7  0.04 cm; p < 0.001) than those
undergoing PN.
The male/female ratio was 1.9:1. There was no difference
between the RN and PN groups for gender (p = 0.23) or
tumor size (p = 0.1). Table 1 lists patient, tumor (including
stage, grade, and histopathological subtypes), and treat-
ment characteristics for the whole cohort.
3.2. Treatment status and changes
3.2.1. Nationwide
There was a 28% overall increase in surgical treatment of
patients with a KC tumor 7 cm. The number of patients
who underwent RN yearly was stable, while the number of
patients undergoing PN doubled from 2008 to 2013
(Supplementary Table 1). Joinpoint regression analysis
[(Fig._1)TD$FIG]
Fig. 1 – Flowchart for data extraction from the main database of the Cancer Registry of Norway according to the inclusion and exclusion criteria.
MIM = minimally invasive method.
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use of RN (Fig. 2). Throughout the study period, 58% of
tumors 4 cm were treated with PN and a significant
increase was observed from 2008 to 2013 (43% vs 66%). Fortumors of 4.1–7 cm, only 14%were treatedwith PN, butwith
an increase from 10% in 2008 to 18% in 2013. The
distribution of treatments and time trends are illustrated
in Figure 3 and Supplementary Figure 1. In the RN group,
Table 1 – Characteristics of patients with a kidney cancer tumor 7 cm (N0M0) surgically treated during 2008–2013
Overall RN PN p value
Patients, n (%) 2420 (100) 1406 (58.1) 1014 (41.9)
Age (yr) <0.001 a
Mean  SEM 63.3  0.2 64.8  0.3 61.2  0.4
Median (range) 65 (18–92) 66 (18–92) 63 (18–89)
Gender, n (%) 0.2 b
Female 845 (35) 505 (36) 340 (34)
Male 1575 (65) 901 (64) 674 (66)
Side, n (%) 0.03 b
Right 1225 (51) 706 523
Left 1178 (49) 697 482
Bilateral 10 (0) 5 5
Not specified 7 (0) 2 5
Tumor size (cm)
Mean  SEM (median) 3.6  0.03 (3.5) 4.3  0.04 (4.4) 2.65  0.04 (2.5) <0.001 a
4 cm (n = 1553) 2.6  0.02 (2.5) 3.0  0.03 (2.2) 2.3  0.03 (3.0) <0.001 a
>4 to 7 cm (n = 867) 5.5  0.03 (5.3) 5.6  0.03 (5.5) 5.0  0.07 (5.0) <0.001a
Subtype, n (%) <0.001 b
Clear cell 1701 (70) 1028 (73) 673 (66)
Papillary 407 (17) 197 (14) 210 (21)
Chromophobe 149 (6) 85 (6) 64 (6)
Multicystic clear cell 76 (3) 35 (2) 41 (4)
Other kidney cancers 87 (4) 61 (4) 26 (3)
Fuhrman grade, n (%) <0.001b
1 269 (11) 124 (9) 145 (14)
2 1314 (54) 742 (53) 572 (56)
3 544 (23) 366 (26) 178 (18)
4 61 (2) 50 (3) 11 (1)
Not specified 232 (10) 124 (9) 108 (11)
T stage, n (%) <0.001 b
pT1a 1497 (62) 614 (44) 883 (87)
pT1b 716 (30) 604 (43) 112 (11)
pT3a 193 (8) 174 (12) 19 (2)
pT3b 9 (0) 9 (1) 0 (0)
pT4 5 (0) 5 (0) 0 (0)
RN = radical nephrectomy; PN = partial nephrectomy; SEM = standard error of the mean.
a According to a t test between the RN and PN groups.
b Exact 2 test for comparison between the RN and PN groups.
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demonstrates the shift in 2010 towards more MIMs. For PN,
MIMuse increased from25% to 64% during the study period,
and 55% of PNs in 2013 were performed with robotic
assistance (vs 7% in 2008). The major shift in the use of PN
occurred from 2010 onwards, including a gradual increase
in MIM. In 2013, the use of robot-assisted laparoscopic PN
(RALPN) surpassed pure laparoscopic PN (Supplementary
Table 1). The use of MIM-PN and open partial nephrectomy
(OPN) was similar between the age groups (<65 vs65 yr);
by contrast, MIM-RNwas used significantlymore often than
open radical nephrectomy (ORN) for patients<65 yr (70% vs
60%; p = 0.004).
3.2.2. Regional and county trends
The geographic distribution of PN versus RN and open versus
MIMs differed significantly between the regions, as illustrated
in Supplementary Figure 2 (p< 0.001). RN was used more
frequently for patients within the SHA (62%) and NHA (63%)
compared to the CHA (55%) and WHA (45%). The most
frequent procedurewas laparoscopic RN (LRN) in the SHA and
OPN in the WHA. In each region, PN increased significantly
from the first to the second half of the study period, but
differences persisted (p< 0.03). The distribution of treatmenttypes by HA and year is shown in Supplementary
Figure 2. Patients living in the 19 counties experienced
divergent treatment strategies, althoughwith a trend towards
an increase in PN use for all counties, as shown in Figure 4.
3.2.3. Hospital trends
The tumor size distribution did not differ between HVHs
and LVHs, althoughHVHs used PN for KC surgerymore often
than LVHs (44% vs 33%; p < 0.001). This was particularly
evident for tumors 4 cm (p < 0.001) but was less
pronounced for tumors of 4.1–7 cm (p = 0.295). PN use
increased from the first to the second period at both HVHs
(from 36% to 51%) and LVHs (from 24% to 38%), despite no
change in tumor size.
3.3. Predictors of treatment
To identify predictors of PN, several factors were entered
into a multivariate logistic regression model (Table 2).
Younger age, smaller tumor size, HVH, second half of the
study period, and WHA and CHA remained independent
predictors. Furthermore, the independent predictors of
undergoing MIM surgery were female gender, HVH, second
half of the study period, and SHA.
[(Fig._2)TD$FIG]
Fig. 2 – Temporal trends in the use of (A) partial nephrectomy and (B) radical nephrectomy for 2420 patients. Data points show the annual frequencies
and the trend line demonstrates the joinpoint regression results. The annual percentage change (APC) was significantly different from zero at
a = 0.05 for partial nephrectomy, indicating a significant increase in this procedure. The small decrease in radical nephrectomy was not statistically
significant.
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Kaplan-Meier plots showed an OS benefit for patients
undergoing PN compared to RN (Supplementary Figs. 3 and
4). On Cox regression analysis, PN was an independent
predictor of OS, as were age, Fuhrman grade, and T stage
(Supplementary Table 2). There was no difference in CSS
between PN and RN when stratified for stage (p = 0.8).
Although the difference is not significant, the 5-yr RS washigher for the PN group (98.1, 95% CI 94.0–99.4) than for the
RN group (92.8, 95% CI 88.1–95.7). For T1b tumors the 5-yr
RS was 98.8 (95% CI 16.3–100.0) after PN and 90.0 (95% CI
85.1–93.3) after RN. Competing-risks analysis (Fig. 5A)
revealed a higher probability of death from competing risks
in the RN group, with early separation of the curves for RN
and PN. However, after splitting other-cause deaths into
other cancers and noncancerous conditions (Fig. 5B), PN and
RN patients had a similar probability of death from a
[(Fig._3)TD$FIG]
Fig. 3 – Comparison of treatments in terms of percentage of procedures per year. (A) All approaches investigated. (B) Open radical nephrectomy
(ORN) versus minimally invasive radical nephrectomy (MIM-RN). (C) Open partial nephrectomy (OPN) versus minimally invasive partial nephrectomy
(MIM-PN).
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separate, and the competing risks increase for RN patients.
Figure 5C shows similar separation of the curves comparing
death from all cancers to death for noncancerous condi-
tions.4. Discussion
The present study clearly demonstrates that the field of KC
surgical care and management is rapidly changing. Over the
past 20 yr the toolbox for personalized surgical treatment of
[(Fig._4)TD$FIG]
Fig. 4 – Distribution and changes in treatment in the 19 counties in Norway in the first half (2008–2010) and second half (2011–2013) of the study
period. PN during (A) 2008–2010 and (B) 2011–2013. (C) PN for tumors 4 cm during (C) 2008–2010 and (D) 2011–2013. MIM-RN for tumors of 4.1–7 cm
during (E) 2008–2010 and (F) 2011–2013. MIM includes pure laparoscopic, hand-assisted, and robot-assisted laparascopic methods. Overall, the
variation in PN among counties ranged from 26% to 59%. The variation in PN rate ranged from 36% to 77% for tumors 4 cm and from 2% to 28% for
tumors of 4.1–7 cm (data not shown). Counties with a PN rate of <25% PN in 2008 doubled the PN rate in 2013, whereas counties with a PN rate of 25–
40% in 2008 increased this to approximately 60% in 2013. Four of the 19 counties generally used PN more often than RN during the study period. From
the first to the second half of the study, the use of MIM-RN for tumors of 4.1–7 cm became more widespread. PN = partial nephrectomy; MIM-
RN = minimally invasive radical nephrectomy.
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Table 2 – Multiple logistic regression analyses to predict PN and MIM in surgically treated kidney cancer patients
Variable PN vs RN (n = 2420) MIM vs open (n = 2396)
OR (95% CI) p value OR (95% CI) p value
Age (continuous in years) 0.97 (0.96–0.98) <0.001 0.99 (0.99–1.00) 0.6
Gender (male vs female) 1.20 (0.97–1.39) 0.20 0.81 (0.67–0.98) 0.03
Tumor size (continuous in cm) 0.42 (0.39–0.45) <0.001 1.02 (0.96–1.07) 0.6
Year of diagnosis <0.001 <0.001
2008–2010 1.00 (reference) 1.00 (reference)
2011–2013 2.17 (1.73–2.58) <0.001 1.93 (1.61–2.31) <0.001
Hospital volume <0.001 <0.001
<20 procedures per year 1.00 (reference) 1.00 (reference)
20 procedures per year 1.87 (1.45–2.46) <0.001 2.2 (1.78–2.88) <0.001
Regional Health Authority <0.001 <0.001
South-Eastern 1.00 (reference) 1.00 (reference)
Western 3.0 (2.26–3.89) <0.001 0.20 (0.16–0.25) <0.001
Central 2.1 (1.55–2.75) <0.001 0.44 (0.34–0.56) <0.001
Northern 1.2 (0.84–1.73) 0.3 0.13 (0.09–0.18) <0.001
PN = partial nephrectomy; RN = radical nephrectomy; MIM = minimally invasive method; OR = odds ratio; CI = confidence interval.
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surgeons had one standard open surgical procedure for all,
but today urologists face multiple choices regarding both
the surgical approach (standard, single site, hand-assisted,
or robot-assisted laparoscopy) and tumor removal (RN vs
PN). Moreover, ablative treatments and surveillance could
be appropriate alternatives. In this changing landscape,
evidence-based guidelines are important contributors in
helping to choose the best treatment for individual KC
patients. One of the important changes demonstrated in
this study is the marked increase in PN following the major
change in the EAU recommendation for PN in 2010. The
overall use of PN in Norway increased from 31% to 49%
between 2008 and 2013. The implementation was greatest
for tumors4 cm (66% in 2013), but was also substantial for
tumors of 4.1–7 cm (18% in 2013). This is in linewith current
evidence-based knowledge on the surgical treatment of
localized KC tumors of 7 cm, which advocates PN rather
than RN whenever feasible [12]. The current data show that
use of PN in Norway is comparable to recent Dutch and
Swedish population-based data. In the Dutch study, the use
of PNwas 62% for T1a and 30% for T1b tumors in 2014, while
in the Swedish study it was 53% for T1a and 9% T1b tumors
[(Fig._5)TD$FIG]Fig. 5 – Competing-risks analysis for partial nephrectomy (PN) and radical nep
from all other causes; (B) from kidney cancer versus other cancers and noncan
versus noncancerous conditions.in 2011 [18,19]. Similar data are also available from the USA
[20,21].
Similar to the morewidespread adoption of PN, MIM use
has also increased. This trend is evident for both MIM-RN
and MIM-PN. MIM is popular among patients because of
lower perioperative morbidity and better cosmetic results
[22]. In studies on quality of life after KC surgery,
laparoscopic procedures performed better than open
surgery [23]. Pure laparoscopic PN is a more challenging
procedure than LRN. It requires considerable surgical
expertise, which may have limited its implementation.
The learning curve for RALPN seems shorter than for pure
laparascopic PN [24], and RALPN is also favorable in terms of
complications, conversions, and ischemia time [25]. Costs
for the purchase and maintenance of the robotic platform
are considerable, and therefore acquisition is not warranted
in every hospital [26,27]. However, when RALPN is available,
it increases the adoption of PN [27,28].
The data from the first half of the present study reflect the
EAU recommendation of PN as an established treatment, and
national guidelines calling for all tumors 4 cm to be
evaluated for PN before treatment [11,29]. These guidelines
offer great latitude for individual surgeons to decide onhrectomy (RN). Probability of death (A) from kidney cancer versus death
cerous conditions; and (C) from all cancers (including kidney cancers)
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change in the 2010 edition of the EAU guidelines was the
recommendation of PN “whenever possible” and of whether
or not to perform LRN onT1 tumors suitable for PN [12]. This
recommendation probably made the decision to continue
performing open RN for all tumors more difficult for LVHs.
The present study demonstrates that regional discrepancies
were less pronounced in 2013 than earlier, and that the
regional treatment patterns seem to have equalized. More
imperative recommendations might have been a key to this
change. It has been demonstrated that surgeons interpret
terms such as “if technically feasible” differently. In a survey
among American urologists, the willingness to offer PN
depended on the surgeon’s preferences, skill, experience,
practice setting, renal tumor caseload, and percentage PN,
rather than just on tumor size and complexity [30]. In a
Canadian study, high-volume surgeons predicted MIM and
academic status predicted PN [31]. Our study lacks data at
the surgeon level, but obviously more imperative guidelines
force changes in management. This could occur with uptake
of new methods or referral to larger centers. The hospital
volumeeffect has been discussed in several publications, and
influences the type of surgery, perioperative complications,
morbidity, and mortality [19,30–32]. In our study, we also
found thatHVHswere independent predictors of PN. Overall,
the present study indicates that the Norwegian urology
community seems to have adapted relatively quickly to
changing guidelines.
In line with other authors [7,19], we found that
Norwegian patients treated with PN experienced better
OS and RS and that PN independently predicted OS.
Earlier publications have partly related this to better
preserved renal function, as chronic renal insufficiency
represents a dose-dependent risk factor for cardiovascular
diseases and events, risk of hospitalization, and mortality
from any cause [4]. However, a meta-analysis by Wang et al
[33] did not indicate that PN reduced the rate of
cardiovascular events.
Newer findings indicate that only selected groups of
patients presenting with preoperative chronic kidney
disease (CKD) or concomitant comorbidity benefit from
PN [34,35] and that worsening of already existing CKD is
faster andmore pronounced after RN than after PN, possibly
leading to more subsequent deaths among RN patients. The
additional contribution of medically induced CKD to
outcome when compared to surgically induced CKD is also
important [36].
There is an ongoing debate on whether the OS gain after
PN is caused by selection bias [37]. Even though our study is
population-based, selection bias and unmeasured confoun-
ders might be present, and should be kept in mind when
considering the degree of survival benefit for PN, as
discussed by others [8,37]. However, our competing-risks
analysis demonstrates that it takes approximately 2 yr
before the noncancermortality rates for PN and RN separate,
indicating a lesser degree of selection bias in this group of
patients. On the basis of our data, we cannot rule out that the
less steep noncancermortality rate is partly due to improved
renal function, but further research is warranted.The present study is not without limitations. The CRN
register data do not include information about tumor
localization and complexity, renal function, or clinical data
such as Charlson comorbidity scores and postoperative
complications. Since hospitals were anonymous, as was
surgeon experience, practice setting, and annual caseload,
their influence on selection and diffusion of treatment could
not be evaluated.
5. Conclusions
In Norway, the rate of PN for KC tumors 7 cm increased
over the study period. For both RN and PN, the rates of open
surgery decreased while the rate of MIM approaches
increased. The rise in PN observed coincides with the
new guidelines recommendations in 2010.
In general, KC treatment practice in Norway is compara-
ble to that in other countries, but with divergent regional
practice patterns. Patients undergoing PN for KC tumors
7 cm may have better OS and RS compared to similar RN
patients, which supports the importance of following
evidence-based guidelines.
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